2018
DOI: 10.1200/jco.2018.36.15_suppl.e21556
|View full text |Cite
|
Sign up to set email alerts
|

Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for BRAF mutant patients from a Brazilian private payer perspective.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles